Last $0.54 USD
Change Today -0.025 / -4.42%
Volume 772.2K
ONCS On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

oncosec medical inc (ONCS) Snapshot

Open
$0.56
Previous Close
$0.56
Day High
$0.56
Day Low
$0.54
52 Week High
03/5/14 - $0.97
52 Week Low
11/25/13 - $0.28
Market Cap
132.1M
Average Volume 10 Days
778.0K
EPS TTM
$-0.06
Shares Outstanding
244.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOSEC MEDICAL INC (ONCS)

Related News

No related news articles were found.

oncosec medical inc (ONCS) Related Businessweek News

No Related Businessweek News Found

oncosec medical inc (ONCS) Details

OncoSec Medical Incorporated, a hybrid device and gene therapy biotechnology company, designs, develops, and commercializes medical approaches principally immunotherapy for the treatment of solid tumors in the United States. Its clinical programs include three Phase II clinical trials to assess the ImmunoPulse technology in patients with melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated is headquartered in San Diego, California.

42 Employees
Last Reported Date: 10/10/14

oncosec medical inc (ONCS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $467.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $310.0K
Chief Scientific Officer and Global Head of R...
Total Annual Compensation: $172.8K
Compensation as of Fiscal Year 2014.

oncosec medical inc (ONCS) Key Developments

Oncosec Medical Incorporated and Plexxikon Inc. Collaborate to Explore Combination Immunotherapy in Preclinical Tumor Studies

OncoSec Medical Inc. announced a preclinical collaboration with Plexxikon Inc., to test the combination of Plexxikon's selective CSF-1R inhibitor with OncoSec's Immunopulse pIL-12. Intratumoral macrophages and other related cell types, like myeloid-derived suppressor cells, can be strongly immunosuppressive and block anti-tumor immunity. Given understanding of IL-12 as a potent driver of immunogenicity and tumor-infiltrating lymphocytes (TILs) and the potential role of tumor-resident myeloid cells in suppressing the anti-tumor effects of TILs, hypothesize that blocking CSF-1R with Plexxikon's selective CSF-1R inhibitor will lead to synergistic effects in the syngeneic B16.F10 melanoma mouse model. Interleukin-12 (IL-12) is an inflammatory cytokine that is believed to be a master regulator of the immune system, and is important in the up-regulation of both the innate and adaptive immune responses. IL-12 is a key driver of the cascade of biological events which ultimately lead to T-cell-specific killing of cancer cells. Moreover, cytokines and chemokines induced by this pathway also increase the recruitment of inflammatory T-cells into tumors.

OncoSec Medical Incorporated Presents at Stifel Healthcare Conference 2014, Nov-19-2014 04:45 PM

OncoSec Medical Incorporated Presents at Stifel Healthcare Conference 2014, Nov-19-2014 04:45 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Punit S. Dhillon, Co-Founder, Chief Executive Officer, President and Director.

OncoSec Medical Incorporated Presents at BIO-Europe 2014, Nov-04-2014 11:30 AM

OncoSec Medical Incorporated Presents at BIO-Europe 2014, Nov-04-2014 11:30 AM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Speakers: Robert Hamilton Pierce, Chief Scientific Officer and Global Head of R&D.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCS:US $0.54 USD -0.025

ONCS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCS.
View Industry Companies
 

Industry Analysis

ONCS

Industry Average

Valuation ONCS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOSEC MEDICAL INC, please visit www.oncosec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.